A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Eligible age
18–74 yrs
Accepts
All genders
Locations
18 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Sponsor: Xenon Pharmaceuticals Inc.
Where it's recruiting
Dothan · Huntsville
Bentonville · Bryant
Bellflower · La Jolla · San Diego · Sherman Oaks …
Hartford
Fort Myers · Gainesville · Riverview
Atlanta
Orland Park
Jefferson
Baltimore
Boston · Methuen · Watertown · Worcester
O'Fallon · Saint Charles
Cherry Hill · Princeton · Toms River
Source: ClinicalTrials.gov · NCT07076407 · last updated 2026-06-02